Aquestive's Anaphylm resubmission accepted, FDA sets March 2027 goal date
The company reported third-quarter 2026 results alongside an update on Anaphylm's regulatory path, ex-U.S. filings and the AQST-108 program.
SEC filing
5 stories
The company reported third-quarter 2026 results alongside an update on Anaphylm's regulatory path, ex-U.S. filings and the AQST-108 program.
SEC filing
The agency classified the resubmission as a Class 2 response, and Aquestive plans a Health Canada submission in the fourth quarter of 2026.
SEC filing
Eton paid $10 million upfront for exclusive U.S. rights to the diazepam seizure-rescue film, with launch targeted for April 2027 pending final FDA approval.
SEC filing (2)
Daly, former Catalyst Pharmaceuticals CEO, joins effective October 14, 2026, as the company prepares for a potential launch of its allergy drug Anaphylm.
SEC filing
The company said new human factors and pharmacokinetic data address the FDA's prior Complete Response Letter for the needle-free anaphylaxis treatment.
SEC filing